The bm|t is pleased to announce that seven of its Investee Part­ners have already closed fund­ing rounds in 2018. Over €10 mil­lion has been raised by Biano GMP, ifesca, JenID, Mas­ter­PIM, OnCG­nos­tics, Pre­ven­ti­cus and SiOp­tica. The money secures funds for impor­tant and value-adding fur­ther developments.
These invest­ment rounds con­tinue the momen­tum from 2017, which saw over €150 mil­lion invested in 21 port­fo­lio com­pa­nies. Kevin Reeder, CEO of bm|t, sees the con­tin­u­a­tion of the fundrais­ing as a great sig­nal for Thuringia and a strong sig­nal to investors to show the attrac­tive­ness of invest­ing in the region. “With two very suc­cess­ful and highly pub­li­cised exits last year — a sale to Face­book and a Nas­daq IPO, bm|t has appeared on the radar screens of many investors. We see a grow­ing inter­est in co-invest­ments together with bm|t here in Thuringia, which will greatly help us catal­yse the next Thuringian champions.”
Of par­tic­u­lar note, two of the 2018 financ­ings drew sev­eral mil­lion euros from out­side Ger­many, with one invest­ment com­ing from Switzer­land and another from Bel­gium. “We know that our com­pa­nies have pow­er­ful inno­va­tions and great sub­stance, and we are pleased that other investors out­side Ger­many have recog­nised this and will work with us as co-investors to move these com­pa­nies for­ward,” Reeder said.

About Biano GMP

BianoGMP GmbH was founded in August 2017 with the aim of estab­lish­ing itself as a GMP ser­vice provider for medium to small batch sizes in the growth seg­ment of oligonu­cleotides, thereby low­er­ing the bar­ri­ers for poten­tial cus­tomers to enter pre­clin­i­cal and clin­i­cal devel­op­ment. In addi­tion, inno­v­a­tive new and fur­ther devel­op­ments in related ser­vices are planned in order to offer cus­tomers the broad­est pos­si­ble spec­trum around GMP-com­pli­ant nucleotide pro­duc­tion from a sin­gle source.
Fur­ther infor­ma­tion on BianoGMP can be found at: bianoscience.com/GMP_Oligonucleotides.

About ifesca

Founded in 2016 in Ilme­nau, ifesca offers deci­sion sup­port solu­tions and ser­vices based on arti­fi­cial intel­li­gence for the energy mar­ket. High-qual­ity fore­casts for energy-related time series and opti­mised oper­a­tions for energy gen­er­a­tion are pro­vided by the spe­cialised IoT plat­form ifesca.AIVA. ifesca’s “as a ser­vice” solu­tions mas­sively help auto­mate deci­sion-mak­ing processes, thereby increas­ing fore­cast qual­ity and reduc­ing man­ual effort and process com­plex­ity. The ser­vices are pro­vided to every par­tic­i­pant in the global energy mar­kets. Work­ing in these mar­kets for over 15 years and hav­ing a sci­en­tific back­ground enables the ifesca team to develop its unpar­al­leled AI solutions.
For more infor­ma­tion on ifesca, please visit: www.ifesca.de ifesca-aiva.com/

About jenID

jenID Solu­tions pro­vides flex­i­ble soft­ware solu­tions for cus­tomers in finan­cial ser­vices, insur­ance, car rental, telecom­mu­ni­ca­tions and other indus­tries, tai­lored to their needs and enabling them to per­form secure, real-time iden­tity ver­i­fi­ca­tion any­where in the world. The com­pany thus knows who is access­ing, using or bor­row­ing its prod­ucts. The jenID thus helps pro­tect the iden­tity of end users and pre­vents fraud.
For more infor­ma­tion on jenID Solu­tions, please visit: www.jenidsolutions.com

About MasterPIM

Mas­ter­PIM devel­ops a browser-based tool for straight­for­ward prod­uct infor­ma­tion man­age­ment (PIM). The mod­u­lar struc­ture enables the map­ping of sim­ple data con­ver­sion up to a fully scal­able enter­prise solu­tion for retail­ers and man­u­fac­tur­ers, with­out large project man­age­ment, with­out lengthy inte­gra­tion processes. Mas­ter PIM delib­er­ately avoids fea­ture-dri­ven onboard­ing processes and instead relies on prag­matic, stan­dard­ised out-of-the-box solutions.
For more infor­ma­tion on Mas­ter­PIM, please visit: http://www.masterpim.de/

About Oncgnostics

oncg­nos­tics GmbH was founded in 2012 as a spin-off from a uni­ver­sity research group at the Uni­ver­sity Women’s Hos­pi­tal in Jena. As a mol­e­c­u­lar diag­nos­tics com­pany, the Jena-based start-up spe­cialises in the diag­no­sis of can­cer. The tests detect char­ac­ter­is­tic epi­ge­netic changes, so-called DNA methy­la­tions, in can­cer cells. The bio­mark­ers, iden­ti­fied and patented with a spe­cial algo­rithm, form the core of the prod­ucts and are the basis of the company.
For more infor­ma­tion about oncg­nos­tics, please visit: http://www.oncgnostics.com/.

About Preventicus

Pre­ven­ti­cus turns a smart­phone into a med­ical mea­sur­ing tool. This makes it pos­si­ble for users to carry out pre­vi­ously com­plex pre­ven­tive exam­i­na­tions at home via smart­phone and to main­tain their own health through pre­cisely tai­lored pre­ven­tive mea­sures. The USP of Pre­ven­ti­cus are supe­rior biosig­nal-ana­lyt­i­cal algo­rithms with high clin­i­cal evi­dence, which enable risk screen­ing via smart­phone. Indi­vid­ual pre­ven­tion mea­sures are derived from the health pro­file, their effect is mon­i­tored and users are con­nected with health partners.
For more infor­ma­tion about Pre­ven­ti­cus, please visit: http://www.preventicus.com/

About SiOptica

The com­pany was founded in Jena in 2013 with the aim of estab­lish­ing inno­v­a­tive and spe­cialised solu­tions in the mar­ket, espe­cially in the field of optics. The com­pany offers tech­nolo­gies in the field of pri­vacy fil­ters that can pro­tect screen data from unau­tho­rised view with­out caus­ing bright­ness loss and can be oper­ated in pub­lic or pri­vate modes. SiOptica’s solu­tions offer great ben­e­fits in the ATM / bank­ing, retail / pay­ment ter­mi­nal, logis­tics / secure access, data secu­rity and con­sumer elec­tron­ics sectors.
For more infor­ma­tion about SiOp­tica, please visit: www.sioptica.com

About bm‑t

The Erfurt-based bm‑t beteili­gungs­man­age­ment Thürin­gen (bm|t) — a sub­sidiary of the Thüringer Auf­baubank — is the first port of call for invest­ments in Thuringia. Cur­rently, bm|t man­ages eight invest­ment funds with a total vol­ume of € 320 mil­lion. bm|t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the com­pany life cycle.
Fur­ther infor­ma­tion on bm|t can be found at: www.bm‑t.com